Free Trial

Reckitt Equities/Credit sell-off on NEC/Enfamil lawsuit concerns

CONSUMER STAPLES
  • RKTLN {RKT LN Equity} cash mids (A3 Pos, A- S) are moving +3-4 wider on the $60m Illinois court decision declaring its Enfamil formula failed to warn of the risk in causing NEC (disease has fatality rate of 15-40%) in premature infants.
  • For a snapshot; it has £1.4b in cash, generates north of £2b in FCF a year & with net debt of £7.2b only runs leverage at 1.9*; curve already trades on wide end (its tight space) of A-/BBB+ peers.
  • Some analyst are noting it has provisioned for this - we see only ~£200m in total provisions & note in annual reports against NEC claims it has; "Any potential costs relating to these actions are not considered probable and cannot be reliably estimated at the current time".
  • It has a reported "hundreds of lawsuits" against Enfamil causing NEC in premature infants. It will appeal the loss.
  • RKTLN has £ & $ lines as well
154 words

To read the full story

Close

Why MNI

MNI is the leading provider

of intelligence and analysis on the Global Fixed Income, Foreign Exchange and Energy markets. We use an innovative combination of real-time analysis, deep fundamental research and journalism to provide unique and actionable insights for traders and investors. Our "All signal, no noise" approach drives an intelligence service that is succinct and timely, which is highly regarded by our time constrained client base.

Our Head Office is in London with offices in Chicago, Washington and Beijing, as well as an on the ground presence in other major financial centres across the world.
  • RKTLN {RKT LN Equity} cash mids (A3 Pos, A- S) are moving +3-4 wider on the $60m Illinois court decision declaring its Enfamil formula failed to warn of the risk in causing NEC (disease has fatality rate of 15-40%) in premature infants.
  • For a snapshot; it has £1.4b in cash, generates north of £2b in FCF a year & with net debt of £7.2b only runs leverage at 1.9*; curve already trades on wide end (its tight space) of A-/BBB+ peers.
  • Some analyst are noting it has provisioned for this - we see only ~£200m in total provisions & note in annual reports against NEC claims it has; "Any potential costs relating to these actions are not considered probable and cannot be reliably estimated at the current time".
  • It has a reported "hundreds of lawsuits" against Enfamil causing NEC in premature infants. It will appeal the loss.
  • RKTLN has £ & $ lines as well